Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack survivors may get Anti-Inflammatory boost from diabetes drug

NCT ID NCT07351643

Disease control Sponsor: Shenyang Northern Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dapagliflozin, a drug typically used for diabetes, can lower inflammation in the heart arteries of people who recently had a heart attack but do not have diabetes or heart failure. About 110 participants will receive either the drug plus standard care or standard care alone for 6 months. Researchers will use CT scans to measure changes in fat around the arteries, which indicates inflammation levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years 2. Diagnosis of acute coronary syndrome (including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, or unstable angina) 3. Undergoing percutaneous coronary intervention (PCI) 4. Presence of multivessel coronary artery disease with at least one non-culprit vessel not undergoing revascularization (for CCTA follow-up assessment) 5. Willing and able to provide written informed consent Exclusion Criteria: 1. Prior or current diagnosis of diabetes mellitus 2. Prior or current diagnosis of chronic heart failure 3. Treatment with any SGLT2 inhibitor within 4 weeks prior to enrollment 4. Severe hepatic impairment 5. History of recurrent urogenital infections 6. Known allergy or intolerance to SGLT2 inhibitors 7. Pregnancy or breastfeeding 8. Systolic blood pressure \<90 mmHg and/or diastolic blood pressure \<60 mmHg 9. Severe chronic kidney disease (eGFR \<30 mL/min/1.73 m²) 10. Current participation in another interventional clinical trial 11. Any other condition that, in the opinion of the investigator, would make the participant unsuitable for enrollment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acs (acute coronary syndrome) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute chest syndrome acute coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acs (acute coronary syndrome) SGLT2 inhibitors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • General Hospital of Northern Theater Command

    Shenyang, Liaoning, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.